Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

Karen B. Jacobson, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues investigated the ...

Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Most children will contract RSV by the time they turn 2 years old. These preventative tips can help limit the spread.

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

Explore the uptake of maternal RSV vaccination and infant protection trends during the 2023-2024 RSV season, focusing on ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

Jacobson, MD, MPH, from Kaiser Permanente Northern California in Oakland, and colleagues investigated uptake of RSVpreF among pregnant women at 32 to 36 weeks of gestation and nirsevimab among ...